Compare GIL & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIL | HALO |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 12.0B |
| IPO Year | 1999 | 2001 |
| Metric | GIL | HALO |
|---|---|---|
| Price | $41.99 | $110.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $82.00 | ★ $101.75 |
| AVG Volume (30 Days) | 1.9M | ★ 2.3M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.11 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | $65.63 | $33.93 |
| Revenue Next Year | $3.64 | $10.74 |
| P/E Ratio | ★ $23.11 | $35.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.93 | $61.23 |
| 52 Week High | $73.70 | $116.85 |
| Indicator | GIL | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 34.81 | 52.97 |
| Support Level | $39.93 | $104.49 |
| Resistance Level | $55.41 | $111.15 |
| Average True Range (ATR) | 1.70 | 3.27 |
| MACD | 0.02 | -0.83 |
| Stochastic Oscillator | 23.42 | 29.98 |
Gildan is a vertically integrated designer and manufacturer of basic apparel, including T-shirts, underwear, socks, and hosiery. It is a leader in blank T-shirts, sweatshirts, and other apparel to wholesalers, major clothing brands, and printers (printwear). Gildan also sells branded clothing through retail and direct-to-consumer channels, a business that has been greatly enhanced by the Hanesbrands acquisition. Gildan's brands include Hanes, Bali, Maidenform, Playtex, Gildan, American Apparel, Comfort Colors, and Goldtoe. Gildan produces most of its clothing at factories in Latin America but has been ramping up production at its new facility in Bangladesh. Incorporated in 1984, the Montreal-based company operates internationally but generated 90% of its sales in the US in 2025.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.